transplantologiyaТрансплантологияTransplantologiya. The Russian Journal of Transplantation2074-05062542-0909IPO Association of Transplantologists10.23873/2074-0506-2017-9-3-211-225transplantologiya-179Research ArticleОБЗОРНЫЕ СТАТЬИ И ЛЕКЦИИREVIEW ARTICLES AND LECTURESИММУНОЛОГИЧЕСКАЯ ТОЛЕРАНТНОСТЬ ПРИ ТРАНСПЛАНТАЦИИ ОРГАНОВIMMUNOLOGICAL TOLERANCE IN ORGAN TRANSPLANTATIONХубутияМ. Ш.KhubutiyaM. Sh.

Могели  Шалвович Хубутия - академик РАН, профессор, президент.

Москва

Mogeli Sh. Khubutiya - Acad. of RAS, Professor, President.

Moscow

sklifos@inbox.ruГуляевВ. А.GulyaevV. A.

Москва

Moscow

ХватовВ. Б.KhvatovV. B.

Москва

Moscow

ЛеменёвВ. Л.LemenevV. L.

Москва

Moscow

КабановаС. А.KabanovaS. A.

Москва

Moscow

НоврузбековМ. С.NovruzbekovM. S.

Москва

Moscow

ЛуцыкК. Н.LutsykK. N.

Москва

Moscow

ОлисовО. Д.OlisovO. D.

Москва

Moscow

ЖуравельС. В.Zhuravel'S. V.

Москва

Moscow

БулаваГ. В.BulavaG. V.

Москва

Moscow

ЦуроваД. Х.TsurovaD. Kh.

Москва

Moscow

БоровковаН. В.BorovkovaN. V.

Москва

Moscow

МироновА. С.MironovА. S.

Москва

Moscow

ЗиминаЛ. Н.ZiminaL. N.

Москва

Moscow

ГБУЗ «НИИ скорой помощи им. Н.В. Склифосовского ДЗМ»РоссияN.V. Sklifosovsky Research Institute for Emergency MedicineRussian Federation20170709201793211225Copyright © Хубутия М.Ш., Гуляев В.А., Хватов В.Б., Леменёв В.Л., Кабанова С.А., Новрузбеков М.С., Луцык К.Н., Олисов О.Д., Журавель С.В., Булава Г.В., Цурова Д.Х., Боровкова Н.В., Миронов А.С., Зимина Л.Н., 20172017Хубутия М.Ш., Гуляев В.А., Хватов В.Б., Леменёв В.Л., Кабанова С.А., Новрузбеков М.С., Луцык К.Н., Олисов О.Д., Журавель С.В., Булава Г.В., Цурова Д.Х., Боровкова Н.В., Миронов А.С., Зимина Л.Н.Khubutiya M.S., Gulyaev V.A., Khvatov V.B., Lemenev V.L., Kabanova S.A., Novruzbekov M.S., Lutsyk K.N., Olisov O.D., Zhuravel' S.V., Bulava G.V., Tsurova D.K., Borovkova N.V., Mironov А.S., Zimina L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jtransplantologiya.ru/jour/article/view/179

Моделирование иммунологической  толерантности  позволит  отказаться  от   приема  лекарственных средств для   профилактики  реакции  отторжения донорского органа.   В  обзоре  литературы  освещаются иммунные механизмы отторжения аллотрансплантата и способы индукции толерантности. Обсуждаются роль  мезенхимальных стволовых клеток и  их применение для  развития  толерантности,  авторы также обращают внимание на то, что  переливание крови от донора  органов  приводит к снижению интенсивности иммунного ответа на донорские клетки при  трансплантации.

Modeling of  immune tolerance will  eliminate the  need  for  taking medications to prevent rejection. This  review of available literature covers the immune mechanisms of allograft rejection and the ways of tolerance induction. The role of mesenchymal stem  cells and using them for tolerance development have been discussed. The authors also draw attention to the fact  that  blood transfusion from an organ donor  leads to a decreased  intensity of the immune response to donor cells in transplantation.

пересадка органовострое отторжениеиммунологическая толерантностьorgan transplantacute rejectionimmunological toleranceReferencesRaychaudhuri S.P., Kundu-Raychaudhuri S., Tamura K., et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J. Invest. Dermatol. 2008;128:1969–1976. PMID:18337836 DOI:10.1038/jid.2008.38Raychaudhuri S.P., Kundu-Raychaudhuri S., Tamura K., et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J. Invest. Dermatol. 2008;128:1969–1976. PMID:18337836 DOI:10.1038/jid.2008.38Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5(6):485–489. PMID:14660044 DOI:10.1080/14653240310003611Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 2003;5(6):485–489. PMID:14660044 DOI:10.1080/14653240310003611Owen R.D. Immunogenetic consequences of vascular anastomoses between bovine twins. Science. 1945;102:400–401. DOI:10.1126/science.102.2651.400 PMID:17755278Owen R.D. Immunogenetic consequences of vascular anastomoses between bovine twins. Science. 1945;102:400–401. DOI:10.1126/science.102.2651.400 PMID:17755278Demikhov V.P. A new and simpler variant of heart-lung preparation of a warm-blooded animal. Bull. Eksp. Biol. Med. 1950; (7): 21–27.Demikhov V.P. A new and simpler variant of heart-lung preparation of a warm-blooded animal. Bull. Eksp. Biol. Med. 1950; (7): 21–27.Hašek M., Puza A. On the induction of immunological tolerance in adult recipients. Folia Biol (Praha). 1962;8:55–57. PMID:13905162Hašek M., Puza A. On the induction of immunological tolerance in adult recipients. Folia Biol (Praha). 1962;8:55–57. PMID:13905162Marsh S.G., Albert E.D., Bodmer W.F., et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291–455. PMID:20356336 DOI:10.1111/j.1399-0039.2010.01466.xMarsh S.G., Albert E.D., Bodmer W.F., et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75(4):291–455. PMID:20356336 DOI:10.1111/j.1399-0039.2010.01466.xMedawar P.B. A second study of the behaviour and fate of skin homografts in rabbits A Report to the War Wounds Committee of the Medical Research Council. J. Anat. 1945;79(Pt 4):157–176.4. PMID:17104981Medawar P.B. A second study of the behaviour and fate of skin homografts in rabbits A Report to the War Wounds Committee of the Medical Research Council. J. Anat. 1945;79(Pt 4):157–176.4. PMID:17104981Хубутия М.Ш. (ред.) Трансплантация органов и тканей в многопрофильном научном центре. М.: АирАрт, 2011. 424 с.Хубутия М.Ш. (ред.) Трансплантация органов и тканей в многопрофильном научном центре. М.: АирАрт, 2011. 424 с.Ruiz P., Maldonado P., Hidalgo Y., et al. Transplant Tolerance: New Insights and Strategies for Long-Term Allograft Acceptance. Clin. Dev. Immu- nol. 2013;2013:210506. PMID:23762087 DOI:10.1155/2013/210506Ruiz P., Maldonado P., Hidalgo Y., et al. Transplant Tolerance: New Insights and Strategies for Long-Term Allograft Acceptance. Clin. Dev. Immu- nol. 2013;2013:210506. PMID:23762087 DOI:10.1155/2013/210506Манько В.М., Девришов Д.А. Вете- ринарная иммунология. Фундаменталь- ные основы. М.: Агровет, 2011. 752 с.Манько В.М., Девришов Д.А. Вете- ринарная иммунология. Фундаменталь- ные основы. М.: Агровет, 2011. 752 с.Oluwole S.F., Oluwole O.O., Adey- eri A.O., DePaz H.A. New strategies in immune tolerance induction. Cell Bio- chem. Biophys. 2004;40(3 Suppl.):27–48. PMID:15289641Oluwole S.F., Oluwole O.O., Adey- eri A.O., DePaz H.A. New strategies in immune tolerance induction. Cell Bio- chem. Biophys. 2004;40(3 Suppl.):27–48. PMID:15289641Nijagal A., Derderian C., Le T., et al. Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. Blood. 2013;121(22):4595–4602. PMID:23610372 DOI:10.1182/blood-2012-10-463174Nijagal A., Derderian C., Le T., et al. Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. Blood. 2013;121(22):4595–4602. PMID:23610372 DOI:10.1182/blood-2012-10-463174Voll R.E., Herrmann M., Roth E.A., et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–351. PMID:9389474 DOI:10.1038/37022Voll R.E., Herrmann M., Roth E.A., et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350–351. PMID:9389474 DOI:10.1038/37022Williams C.A., Harry R.A., McLeod J.D. Apoptotic cells induce dendritic cell-mediated suppression via interferon--induced IDO. Immunology. 2008;124(1):89–101. PMID:18067553 DOI:10.1111/j.1365-2567.2007.02743.xWilliams C.A., Harry R.A., McLeod J.D. Apoptotic cells induce dendritic cell-mediated suppression via interferon--induced IDO. Immunology. 2008;124(1):89–101. PMID:18067553 DOI:10.1111/j.1365-2567.2007.02743.xEzzelarab M., Thomson A.W. Tolerogenic dendritic cells and their role in transplantation. Semin. Immunol. 2011;23(4):252–263. PMID:21741270 DOI:10.1016/j.smim.2011.06.007Ezzelarab M., Thomson A.W. Tolerogenic dendritic cells and their role in transplantation. Semin. Immunol. 2011;23(4):252–263. PMID:21741270 DOI:10.1016/j.smim.2011.06.007Hu J., Wan Y. Tolerogenic dendritic cells and their potential applications. Immunology. 2011;132(3):307–314. PMID:21208205 DOI:10.1111/j.1365-2567.2010.03396.xHu J., Wan Y. Tolerogenic dendritic cells and their potential applications. Immunology. 2011;132(3):307–314. PMID:21208205 DOI:10.1111/j.1365-2567.2010.03396.xLewis K.L., Reizis B. Dendritic Cells: Arbiters of Immunity and Immunological Tolerance. Cold Spring Harb. Perspect. Biol. 2012;4(8):a007401. PMCID:PMC3405856 DOI:10.1101/cshperspect.a007401Lewis K.L., Reizis B. Dendritic Cells: Arbiters of Immunity and Immunological Tolerance. Cold Spring Harb. Perspect. Biol. 2012;4(8):a007401. PMCID:PMC3405856 DOI:10.1101/cshperspect.a007401Монастырская Е.А., Лямина С.В., Малышев И.Ю. М1 и М2 фенотипы активированных макрофагов и их роль в иммунном ответе и патологии. Патогенез. 2008;6(4):31–39.Монастырская Е.А., Лямина С.В., Малышев И.Ю. М1 и М2 фенотипы активированных макрофагов и их роль в иммунном ответе и патологии. Патогенез. 2008;6(4):31–39.Sutterwala F.S., Noel G.J., Salgame P., Mosser D.M. Reversal of proinflammatory responses by ligating the macrophage Fc receptor type I. J. Exp. Med. 1998;188(1):217–222. PMID:9653099Sutterwala F.S., Noel G.J., Salgame P., Mosser D.M. Reversal of proinflammatory responses by ligating the macrophage Fc receptor type I. J. Exp. Med. 1998;188(1):217–222. PMID:9653099Lafferty K.J., Prowse S.J., Simeonovic C.J., Warren H.S. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1983;1:143–173. PMID:6443557 DOI:10.1146/annurev.iy.01.040183.001043Lafferty K.J., Prowse S.J., Simeonovic C.J., Warren H.S. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1983;1:143–173. PMID:6443557 DOI:10.1146/annurev.iy.01.040183.001043Bretscher P., Cohn M. A theory of self-nonself discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science. 1970;169:1042–1049. PMID:4194660Bretscher P., Cohn M. A theory of self-nonself discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science. 1970;169:1042–1049. PMID:4194660Lassila O., Vainio O., Matzinger P. Can B cells turn on virgin T cells? Nature. 1988;334:253–255. PMID:2969460 DOI:10.1038/334253a0Lassila O., Vainio O., Matzinger P. Can B cells turn on virgin T cells? Nature. 1988;334:253–255. PMID:2969460 DOI:10.1038/334253a0Ashwell J.D., Jenkins M.K., Schwartz R.H. Effect of gamma radiation on resting B lymphocytes. II. Functional characterization of the antigen-presentation defect. J. Immunol. 1988;141(8):2536–2254. PMID:2844902Ashwell J.D., Jenkins M.K., Schwartz R.H. Effect of gamma radiation on resting B lymphocytes. II. Functional characterization of the antigen-presentation defect. J. Immunol. 1988;141(8):2536–2254. PMID:2844902Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156–1159. PMID:1439825Fuchs E.J., Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156–1159. PMID:1439825Billingham R.E., Brent L., Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172:603–606. PMID:13099277Billingham R.E., Brent L., Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172:603–606. PMID:13099277Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993;177(4):925–935. PMID:7681471Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J. Exp. Med. 1993;177(4):925–935. PMID:7681471Фрейдлин И.С. Регуляторные Т-клетки: происхождение и функции. Медицинская иммунология. 2005;7(4):347–354 DOI:10.15789/1563-0625-2005-4-347-354Фрейдлин И.С. Регуляторные Т-клетки: происхождение и функции. Медицинская иммунология. 2005;7(4):347–354 DOI:10.15789/1563-0625-2005-4-347-354Marino J., Paster J., Benichou G. Allorecognition by T Lymphocytes and Allograft Rejection. Front. Immunol. 2016;7:582. PMID:28018349 DOI:10.3389/fimmu.2016.00582.eCollection 2016Marino J., Paster J., Benichou G. Allorecognition by T Lymphocytes and Allograft Rejection. Front. Immunol. 2016;7:582. PMID:28018349 DOI:10.3389/fimmu.2016.00582.eCollection 2016Vincenti F., Dritselis A., Kirkpatrick P. Belatacept. Nat. Rev. Drug. Discov. 2011;10(9):655–656. PMID:21878974 DOI:10.1038/nrd3536Vincenti F., Dritselis A., Kirkpatrick P. Belatacept. Nat. Rev. Drug. Discov. 2011;10(9):655–656. PMID:21878974 DOI:10.1038/nrd3536Cohen J.B., Eddinger K.C., Forde K.A., et al. Belatacept Compared to Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. Transplantation. 2016; [Epub ahead of print] PMID:27941427 DOI:10.1097/TP.0000000000001589Cohen J.B., Eddinger K.C., Forde K.A., et al. Belatacept Compared to Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study. Transplantation. 2016; [Epub ahead of print] PMID:27941427 DOI:10.1097/TP.0000000000001589Goring S.M., Levy A.R., Ghement I., et al. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr. Med. Res. Opin. 2014;30(8):1473–1487. PMID:24628478 DOI:10.1185/03007995.2014.898140Goring S.M., Levy A.R., Ghement I., et al. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr. Med. Res. Opin. 2014;30(8):1473–1487. PMID:24628478 DOI:10.1185/03007995.2014.898140Durrbach A., Pestana J.M., Florman S., et al. Long-Term outcomes in Belatacept Versus Cyclosporine-Treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a Phase III Randomized Study. Am. J. Transplant. 2016;16(11):3192–3201. PMID:27130868 DOI:10.1111/ajt.13830Durrbach A., Pestana J.M., Florman S., et al. Long-Term outcomes in Belatacept Versus Cyclosporine-Treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a Phase III Randomized Study. Am. J. Transplant. 2016;16(11):3192–3201. PMID:27130868 DOI:10.1111/ajt.13830Masson P., Henderson L., Chapman J.R., et al. Belatacept for kidney transplant recipients. Cochrane Database Syst. Rev. 2014;(11):CD010699. PMID:25416857 DOI:10.1002/14651858.CD010699.pub2Masson P., Henderson L., Chapman J.R., et al. Belatacept for kidney transplant recipients. Cochrane Database Syst. Rev. 2014;(11):CD010699. PMID:25416857 DOI:10.1002/14651858.CD010699.pub2Hu M., Wang C., Zhang G.Y., et al. Infiltrating Foxp3(+) regulatory T cells from spontaneously tolerant kidney allografts demonstrate donor-specific tolerance. Am. J. Transplant. 2013;13(11):2819–2830. PMID:24102948 doi:10.1111/ajt.12445Hu M., Wang C., Zhang G.Y., et al. Infiltrating Foxp3(+) regulatory T cells from spontaneously tolerant kidney allografts demonstrate donor-specific tolerance. Am. J. Transplant. 2013;13(11):2819–2830. PMID:24102948 doi:10.1111/ajt.12445Shalev I., Selzner N., Shyu W., et al. Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl. 2012;18(7):761–770. PMID:22523007 DOI:10.1002/lt.23458Shalev I., Selzner N., Shyu W., et al. Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl. 2012;18(7):761–770. PMID:22523007 DOI:10.1002/lt.23458Juvet S.C., Whatcott A.G., Bushell A.R., Wood K.J. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am. J. Transplant. 2014;14(4):750–763. PMID:24592900 DOI:10.1111/ajt.12647Juvet S.C., Whatcott A.G., Bushell A.R., Wood K.J. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am. J. Transplant. 2014;14(4):750–763. PMID:24592900 DOI:10.1111/ajt.12647Singh K., Stempora L., Donald Harvey R., et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am. J. Transplant. 2014;14(12):2691–2703. PMID:25359003 DOI:10.1111/ajt.12934Singh K., Stempora L., Donald Harvey R., et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am. J. Transplant. 2014;14(12):2691–2703. PMID:25359003 DOI:10.1111/ajt.12934Fisher S.A., Lamikanra A., Dorée C. Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review. Br. J. Haematol. 2017;176(3):448–463. PMID:28094847 DOI:10.1111/bjh.14433Fisher S.A., Lamikanra A., Dorée C. Increased regulatory T cell graft content is associated with improved outcome in haematopoietic stem cell transplantation: a systematic review. Br. J. Haematol. 2017;176(3):448–463. PMID:28094847 DOI:10.1111/bjh.14433Alessandrini A., Turka L.A. FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance. Am J Kidney Dis. 2017;69(5):667–674. PM-ID:28049555 DOI:10.1053/j.ajkd.2016.10.027Alessandrini A., Turka L.A. FOXP3-Positive Regulatory T Cells and Kidney Allograft Tolerance. Am J Kidney Dis. 2017;69(5):667–674. PM-ID:28049555 DOI:10.1053/j.ajkd.2016.10.027Noyan F., Zimmermann K., Hardtke-Wolenski M. Prevention of allograft rejection by use of regulatory T cells with a MHC-specific chimeric antigen receptor. Am J Transplant. 2017;17(4):917–930. PMID:27997080 DOI:10.1111/ajt.14175Noyan F., Zimmermann K., Hardtke-Wolenski M. Prevention of allograft rejection by use of regulatory T cells with a MHC-specific chimeric antigen receptor. Am J Transplant. 2017;17(4):917–930. PMID:27997080 DOI:10.1111/ajt.14175Abe Y., Urakami H., Ostanin D., et al. Induction of Foxp3-Expressing Regulatory T-Cells by Donor Blood Transfusion Is Required for Tolerance to Rat Liver Allografts. PLoS One. 2009;4(11):e7840. PMID:19956764 DOI:10.1371/journal.pone.0007840Abe Y., Urakami H., Ostanin D., et al. Induction of Foxp3-Expressing Regulatory T-Cells by Donor Blood Transfusion Is Required for Tolerance to Rat Liver Allografts. PLoS One. 2009;4(11):e7840. PMID:19956764 DOI:10.1371/journal.pone.0007840Dummer C.D., Carpio V.N., Gonçalves L.F., et al. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl. Immunol. 2012;26(1):1–10. DOI:10.1016/j.trim.2011.08.009Dummer C.D., Carpio V.N., Gonçalves L.F., et al. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl. Immunol. 2012;26(1):1–10. DOI:10.1016/j.trim.2011.08.009Zhang L.F., Xia C.Q. Ex vivo expansion of regulatory T cells for clinical applications against graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Chin. Med. J. (Engl). 2013;126(23):4575–4582. PMID:24286428Zhang L.F., Xia C.Q. Ex vivo expansion of regulatory T cells for clinical applications against graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Chin. Med. J. (Engl). 2013;126(23):4575–4582. PMID:24286428Tang Q. Pharmacokinetics of Therapeutic Tregs. Am. J. Transpl. 2014;14(12):2679–2680. doi:10.1111/ajt.12933. PMID:25358900Tang Q. Pharmacokinetics of Therapeutic Tregs. Am. J. Transpl. 2014;14(12):2679–2680. doi:10.1111/ajt.12933. PMID:25358900Pilat N., Klaus C., Gattringer M., et al. Therapeutic efficacy of polyclonal Tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation. 2011;92(3):280–288. PMID:21697774 DOI:10.1097/TP.0b013e3182241133Pilat N., Klaus C., Gattringer M., et al. Therapeutic efficacy of polyclonal Tregs does not require rapamycin in a low-dose irradiation bone marrow transplantation model. Transplantation. 2011;92(3):280–288. PMID:21697774 DOI:10.1097/TP.0b013e3182241133Vanikar A.V., Trivedi H.L., Feroze A., et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hyporesponsiveness. Int. Urol. Nephrol. 2011;43(1):225–232. PMID:20084457 DOI:10.1007/s11255-009-9659-1Vanikar A.V., Trivedi H.L., Feroze A., et al. Effect of co-transplantation of mesenchymal stem cells and hematopoietic stem cells as compared to hematopoietic stem cell transplantation alone in renal transplantation to achieve donor hyporesponsiveness. Int. Urol. Nephrol. 2011;43(1):225–232. PMID:20084457 DOI:10.1007/s11255-009-9659-1Miyairi S., Hirai T., Ishii R., et al. Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance. Eur. J. Immunol. 2017;47(4):734–742 PMID:28127757 DOI:10.1002/eji.201646670Miyairi S., Hirai T., Ishii R., et al. Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance. Eur. J. Immunol. 2017;47(4):734–742 PMID:28127757 DOI:10.1002/eji.201646670Hsu W.T., Lin C.H., Chiang B.L., et al. Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-+CD4+ regulatory T cells to control transplant arteriosclerosis. J. Immunol. 2013;190(5):2372–2380. PMID:23359497 DOI:10.4049/jimmunol.1202996Hsu W.T., Lin C.H., Chiang B.L., et al. Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-+CD4+ regulatory T cells to control transplant arteriosclerosis. J. Immunol. 2013;190(5):2372–2380. PMID:23359497 DOI:10.4049/jimmunol.1202996Crop M.J., Baan C.C., Korevaar S.S., et al. Donor-derived mesen-chymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation. 2009;87(6):896–906. PMID:19300194 DOI:10.1097/TP.0b013e31819b3d72Crop M.J., Baan C.C., Korevaar S.S., et al. Donor-derived mesen-chymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation. 2009;87(6):896–906. PMID:19300194 DOI:10.1097/TP.0b013e31819b3d72Peng Y., Ke M., Xu L., et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: A Clinical Pilot Study. Transplantation. 2013;95(1):161–168. PMID:23263506 DOI:10.1097/TP.0b013e3182754c53Peng Y., Ke M., Xu L., et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: A Clinical Pilot Study. Transplantation. 2013;95(1):161–168. PMID:23263506 DOI:10.1097/TP.0b013e3182754c53Tan J., Wu W., Xu X., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307(11):1169–1177. PMID:22436957 DOI:10.1001/jama.2012.316Tan J., Wu W., Xu X., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307(11):1169–1177. PMID:22436957 DOI:10.1001/jama.2012.316Popp F.C., Renner P., Eggenhofer E., et al. Dahlke mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl. 2009;15;1192–1198. PMID:19790154 DOI:10.1002/lt.21862Popp F.C., Renner P., Eggenhofer E., et al. Dahlke mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl. 2009;15;1192–1198. PMID:19790154 DOI:10.1002/lt.21862Xu G., Zhang L., Ren G., et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell. Res. 2007;17:240–248. PMID:17325691 DOI:10.1038/cr.2007.4Xu G., Zhang L., Ren G., et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell. Res. 2007;17:240–248. PMID:17325691 DOI:10.1038/cr.2007.4Aggarwal S., Pittenger M.F. Human mesenchymal stem cells mod-ulate allogeneic immune cell responses. Blood. 2005;105(4):1815–1822. PMID:15494428 DOI:10.1182/blood-2004-04-1559Aggarwal S., Pittenger M.F. Human mesenchymal stem cells mod-ulate allogeneic immune cell responses. Blood. 2005;105(4):1815–1822. PMID:15494428 DOI:10.1182/blood-2004-04-1559Ryan J.M., Barry F., Murphy J.M., Mahon B.P. Interferongamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007;149(2):353–363. PMID:17521318 DOI:10.1111/j.1365-2249.2007.03422.xRyan J.M., Barry F., Murphy J.M., Mahon B.P. Interferongamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007;149(2):353–363. PMID:17521318 DOI:10.1111/j.1365-2249.2007.03422.xPopp F.C., Eggenhofer E., Renner P., et al. Mesenchymal stem cells can induce longterm acceptance of solid organ allografts in synergy with lowdose mycophenolate. Transpl. Immunol. 2008;20(1–2):55–60. PMID:18762258 DOI:10.1016/j.trim.2008.08.004Popp F.C., Eggenhofer E., Renner P., et al. Mesenchymal stem cells can induce longterm acceptance of solid organ allografts in synergy with lowdose mycophenolate. Transpl. Immunol. 2008;20(1–2):55–60. PMID:18762258 DOI:10.1016/j.trim.2008.08.004Kishimoto K., Yuan X., Auchincloss H.Jr., et al. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J. Am. Soc. Nephrol. 2004;15:2423–2428. PMID:15339991 DOI:10.1097/01.ASN.0000137883.20961.2DKishimoto K., Yuan X., Auchincloss H.Jr., et al. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J. Am. Soc. Nephrol. 2004;15:2423–2428. PMID:15339991 DOI:10.1097/01.ASN.0000137883.20961.2DDave S.D., Vanikar A., Trivedi H.L., et al. Stem cells versus donor specific transfusions for tolerance induction in living donor renal transplantation: a single-center experience. Transplantation. 2013;95(1):155–160. PMID:23263505 DOI:10.1097/TP.0b013e3182752bccDave S.D., Vanikar A., Trivedi H.L., et al. Stem cells versus donor specific transfusions for tolerance induction in living donor renal transplantation: a single-center experience. Transplantation. 2013;95(1):155–160. PMID:23263505 DOI:10.1097/TP.0b013e3182752bccЮдин С.С. Вопросы военно-полевой хирургии и переливание посмертной крови. М.: Медгиз, 1960: 309–393.Юдин С.С. Вопросы военно-полевой хирургии и переливание посмертной крови. М.: Медгиз, 1960: 309–393.Никулина В.П., Гуляев В.А., Годков М.А., Кобзева Е.Н. Иммунологические аспекты использования эритроцитарной массы донора органа при трансплантации печени. В сб.: Хубутия М.Ш. (ред.) Актуальные вопросы трансплантации органов: материалы гор. науч.-практ. конф. М.: Триада, 2008: 93–95.Никулина В.П., Гуляев В.А., Годков М.А., Кобзева Е.Н. Иммунологические аспекты использования эритроцитарной массы донора органа при трансплантации печени. В сб.: Хубутия М.Ш. (ред.) Актуальные вопросы трансплантации органов: материалы гор. науч.-практ. конф. М.: Триада, 2008: 93–95.Khubutia M., Zhuravel S., Gulyaev V., et al. Using of Blood from Cadaveric Donor in Orthotopic liver Transplantation. Bull. Georg. Nat. Acad. Sci. 2014;8(3):108–115.Khubutia M., Zhuravel S., Gulyaev V., et al. Using of Blood from Cadaveric Donor in Orthotopic liver Transplantation. Bull. Georg. Nat. Acad. Sci. 2014;8(3):108–115.

The authors declare that there are no conflicts of interest present.